BioRestorative gets exclusive patent rights for BRTX's BRTX 100 product

BioRestorative Therapies, Inc. BRTX, a stem cell-based therapies clinical-stage company, forged an agreement with Regenexx, LLC, under which BRTX gets exclusive license rights for intellectual property developed to address chronic lumbar disc disease.

The intellectual property, now exclusively licensed to BioRestorative, represents the critical technological framework for BRTX's disc and spine technology related to its BRTX 100 lead clinical program, currently in Phase 2 of a Phase 2 trial with 15 sites selected across the U.S.

Christopher Centeno developed intellectual property in his lab. For over 17 years, Centeno has been a leader in cellular therapy for musculoskeletal indications.

The BRTX 100 platform is a cell-based technology that utilizes low oxygen hypoxia to create a modulation strategy that uses low oxygen hypoxia to repress or activate target genes related to tissue remodeling.

Data from early investigator-initiated human studies suggest a potential platform to regulate target hypoxia-dependent gene expression to improve the efficacy and safety of first-generation cell-based therapies, BioRestorative said.

Today's announcement shows our ability to prosecute intellectual property into issued patents and show significant advancement in clinical settings as a result of years of dedicated work. With the anticipated growth of our R&D pipeline, the acceleration of our Brown Fat platform, and findings from the safety component of our Phase 2 clinical trial in chronic lumbar disc degeneration, we anticipate strong momentum will extend through 2023, Lance Alstodt, CEO of BioRestorative, told Benzinga.

BioRestorative aims to create a new generation of cell-based products that can provide long-term and sustained pain relief for patients suffering from musculoskeletal indications.

Every year, around $40 billion is spent on surgical procedures. With BRTX 100, the company is trying to provide a paradigm-shifting, non-invasive solution to millions of patients worldwide, Alstodt said.

Price Action: BRTX shares went up by 6.59% to $3.56 on Friday.